NOV:F:F-Novo Nordisk A/S (EUR)

COMMON STOCK | Biotechnology |

Last Closing

USD 121.86

Change

0.00 (0.00)%

Market Cap

USD 526.04B

Volume

5.22K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-14 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NOVA:F Novo Nordisk A/S

-4.00 (-3.25%)

USD 547.87B
RGO:F Regeneron Pharmaceuticals Inc

-11.50 (-1.11%)

USD 114.77B
CSJ:F CSL Limited

+0.48 (+0.27%)

USD 88.37B
CSJA:F CSL LTD SPON.ADR 2

N/A

USD 87.08B
UNC0:F UCB S.A. UNSP.ADR 1/2

+1.00 (+1.24%)

USD 30.35B
DUL:F Alnylam Pharmaceuticals Inc

+4.00 (+1.69%)

USD 30.08B
1AEA:F argenx SE

N/A

USD 29.18B
1AE:F Argen-X

-1.50 (-0.31%)

USD 29.17B
22UA:F BioNTech SE

+2.60 (+2.36%)

USD 26.15B
0QF:F Moderna Inc

+2.63 (+4.23%)

USD 24.08B

ETFs Containing NOV:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 30.19% 78% C+ 86% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 30.19% 77% C+ 78% C+
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 526.04B 100% F 100% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.